1. Home
  2. EVAX

EVAX

Evaxion Biotech A/S

Logo Evaxion Biotech A/S

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Founded: 2008 Country:
Denmark
Denmark
Employees: N/A City: N/A
Market Cap: 21.4M IPO Year: 2021
Target Price: $11.00 AVG Volume (30 days): 701.1K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -8.10 EPS Growth: N/A
52 Week Low/High: $2.82 - $18.50 Next Earning Date: 05-29-2024
Revenue: $73,000 Revenue Growth: N/A
Revenue Growth (this year): 6652.05% Revenue Growth (next year): 280.54%

Share on Social Networks: